FRIDAY, JUNE 22

3:00 p.m.-9:30 p.m.  Registration
Registration Desk B

6:00 p.m.-8:00 p.m.  Welcome and Opening
Keynote Address
Salon E

6:00 p.m.-6:07 p.m.  Welcome from
AACR Chief Executive Officer
Margaret Foti, American
Association for Cancer Research, Philadelphia, PA

6:07 p.m.-6:15 p.m.  Welcome from
Scientific Committee Chair
Ari M. Melnick, Weill Cornell
Medical College, New York, NY

6:15 p.m.-6:45 p.m.  Keynote Address: Immunogenicity
predicts prevention
Michael A. Caligiuri, City of Hope, Duarte, CA

6:45 p.m.-7:30 p.m.  Keynote Address: CAR T for
lymphoma and beyond
Carl H. June, University of Pennsylvania, Philadelphia, PA

7:30 p.m.-8:00 p.m.  Panel discussion
Ari M. Melnick
Michael A. Caligiuri
Carl H. June

8:00 p.m.-10:00 p.m.  Opening Reception
Salon F
SATURDAY, JUNE 23

7:00 a.m.-8:00 a.m.   Breakfast
Salon F

7:15 a.m.-8:00 a.m.   Concurrent Sessions 1-2

Concurrent Session 1: Canine Lymphoma as a Surrogate for Human Lymphomas: What Can We Learn from Canine Clinical Trials?
Salons B-D

Session Cochairs: Luca Aresu, University of Turin, Grugliasco, Italy, and Kristy L. Richards, Cornell University, Ithaca, NY

7:15 a.m-8:00 a.m  Panel discussion
Luca Aresu
Cheryl A. London,
Tufts Medical Center, Boston, MA
Laura Marconato,
Centro Oncologico Veterinario,
Sasso Marconi, Italy
Kristy L. Richards

Concurrent Session 2: What Is the Optimal Therapeutic Approach to NHL in Adolescents and Young Adults: A Discussion from the Pediatric and Adult Perspectives
Salon E

Session Chair: Lisa G. Roth, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY

7:15 a.m.-8:00 a.m.  Panel discussion
Kieron Dunleavy,
George Washington University,
Washington, DC
Lisa G. Roth
CONFERENCE SCHEDULE

8:00 a.m.-10:30 a.m.  **Plenary Session 1: Are We Ready for Lymphoma MATCH Trials?**  
Salon E

**Session Chair:** Anas Younes, Memorial Sloan Kettering Cancer Center, New York, NY

8:00 a.m.-8:25 a.m  
**Precision medicine based on the genetic taxonomy of DLBCL**  
Louis M. Staudt, National Cancer Institute, Bethesda, MD

8:25 a.m.-8:50 a.m.  
**How to design a MATCH trial for lymphoma**  
Anas Younes

8:50 a.m.-9:15 a.m.  
**Practical considerations for using genome sequencing data for patient selection**  
David W. Scott, BC Cancer Agency, Vancouver, BC, Canada

9:15 a.m.-9:40 a.m.  
**Molecular typing in DLBL: Subset and match?**  
Peter W. M. Johnson, University of Southampton, Southampton, United Kingdom

9:40 a.m.-9:55 a.m.  
**Utilizing genomic sequencing from clinical assays in lymphoma management**  
Connie Batlevi, Memorial Sloan Kettering Cancer Center, New York, NY

9:55 a.m.-10:30 a.m.  
**Panel discussion**  
Connie Batlevi  
Peter W.M. Johnson  
David W. Scott  
Louis M. Staudt  
Anas Younes

10:30 a.m.-11:00 a.m.  **Break**  
Salons A-E Foyer
11:00 a.m.-11:30 a.m. **Spotlight on Proffered Papers Session 1**  
(from posters in Session A)  
Salon E

11:00 a.m.-11:15 a.m. **Drugs in the curative RCHOP combination exhibit low cross-resistance but not pharmacologic synergy**  
Adam C. Palmer, Harvard Medical School, Boston, MA

11:15 a.m.-11:30 a.m. **MHC class II expression is associated with a distinct mutational profile and immune cell landscape of the microenvironment in GCB-DLBCL**  
Daisuke Ennishi, BC Cancer Agency, Vancouver, BC, Canada

11:45 a.m.-1:45 p.m. **Poster Session A / Lunch**  
Salon F

Lymphoid Cancers 1

Basic and Translational Science 1

Other Topics

Therapeutics and Clinical Trials in Lymphoma 1

2:00 p.m.-4:00 p.m. **Plenary Session 2: Targeting the Epigenome of DLBCL**  
Salon F

**Session Cochairs:** Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland, and Laura Pasqualucci, Columbia University Institute for Cancer Genetics, New York, NY

2:00 p.m.-2:25 p.m. **DNA and histone methylation as therapeutic targets in lymphoma**  
Ari M. Melnick, Weill Cornell Medical College, New York, NY
2:25 p.m.-2:50 p.m.  Targeting EZH2 in lymphoma
Vincent Ribrag, Institut Gustave-Roussy, Villejuif, France

2:50 p.m.-3:15 p.m.  Germinal center-derived lymphomas: At the intersection of genetics and epigenetics
Laura Pasqualucci

3:15 p.m.-3:40 p.m.  BET inhibitors in lymphoma
Francesco Bertoni

3:30 p.m.-4:00 p.m.  Panel discussion
Francesco Bertoni
Ari M. Melnick
Laura Pasqualucci
Vincent Ribrag

4:00 p.m.-4:30 p.m.  Break
Salons A-E Foyer

4:30 p.m.-6:30 p.m.  Plenary Session 3: Can Liquid Biopsies Replace Tissue and Be Used to Guide Clinical Decisions?
Salon E

Session Chair: Davide Rossi, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland

4:30 p.m.-5:00 p.m.  Circulating tumor DNA to monitor treatment response and detect resistant clones in indolent lymphoproliferative diseases treated with novel therapies
Constantine S. Tam, Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia
5:00 p.m.-5:30 p.m. **Tumor fingerprints in the liquid biopsy: Immunoglobulin gene rearrangement or CAPP-seq?**
Wyndham H. Wilson, National Cancer Institute, Bethesda, MD

5:30 p.m.-6:00 p.m. **Use of circulating tumor DNA to genotype aggressive lymphomas**
Davide Rossi

6:00 p.m.-6:30 p.m. **Panel discussion**
Lee M. Greenberger, The Leukemia & Lymphoma Society, Rye Brook, NY
Davide Rossi
Constantine S. Tam
Wyndham H. Wilson

6:30 p.m. **Dinner on own**

**SUNDAY, JUNE 24**

7:00 a.m.-8:00 a.m. **Breakfast**
Salon F

7:15 a.m.-8:00 a.m. **Concurrent Sessions 3-4**

**Concurrent Session 3: What Is the Current Role and Impact of CRISPR Screening to Define Therapeutic Targets in Lymphoma?**
Salons B-D

**Session Chair:** Hans-Guido Wendel, Memorial Sloan Kettering Cancer Center, New York, NY
7:15 a.m.-7:30 a.m. Using in vivo CRISPR-based screening to identify lymphoma drug targets
Michael T. Hemann, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA

7:30 a.m.-7:45 a.m. Title to be announced
Sandeep S. Dave, Duke University, Durham, NC

7:45 a.m.-8:00 a.m. Crispr-Cas9 screens interrogate lymphoma biology and lead to therapies
Hans-Guido Wendel

Concurrent Session 4: Genetic and Molecular Heterogeneity between Western and Asian Lymphoma Patients
Salon E

Session Chair: Wei-Li Zhao, Ruijin Hospital, Shanghai Institute of Hematology, Shanghai, China

7:15 a.m.-7:30 a.m. Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma: Insights for novel targeted therapies
Qiang Pan-Hammarström, Karolinska Institute, Stockholm, Sweden

7:30 a.m.-7:45 a.m. The genetics of marginal zone lymphomas
Davide Rossi, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland

7:45 a.m.-8:00 a.m. Precise classification and treatment of NK/T and T-cell lymphoma
Wei-Li Zhao
8:00 a.m.-10:30 a.m.  **Plenary Session 4: Will CAR T Cells Replace BMT as a Modality for NHL?**
Salon E

**Session Chair:** Renier J. Brentjens, Memorial Sloan Kettering Cancer Center, New York, NY

8:00 a.m.-8:30 a.m.  **Contemporary salvage therapy and autologous transplantation for relapsed and primary refractory DLBCL: The low bar has been firmly set**
Craig S. Sauter, Memorial Sloan Kettering Cancer Center, New York, NY

8:30 a.m.-9:00 a.m.  **Clinical overview of CAR T cell therapy in relapsed/refractory diffuse large B-cell lymphoma: Promise and limitations**
Michael R. Bishop, University of Chicago, Chicago, IL

9:00 a.m.-9:30 a.m.  **Next-gen T cells**
Renier J. Brentjens

9:30 a.m.-10:00 a.m.  **CARS versus autos or CARS plus autos?**
Stephen J. Forman, City of Hope, Duarte, CA

10:00 a.m.-10:30 a.m.  **Panel discussion**
Michael R. Bishop
Renier J. Brentjens
Stephen J. Forman
Craig S. Sauter

10:30 a.m.-11:00 a.m.  **Break**
Salons A-E Foyer
CONFERENCE SCHEDULE

11:00 a.m.-11:30 a.m.  **Spotlight on Proffered Papers Session 2**  
(from posters in Session B)  
Salon E

11:00 a.m.-11:15 a.m.  **Lenalidomide treatment restores in vivo T-cell activity in relapsed/refractory FL and DLBCL**  
Cedric Menard, University of Rennes, Rennes, France

11:15 a.m.-11:30 a.m.  **Anti-CD37 chimeric antigen receptor T cells: A new potential therapeutic option for non-Hodgkin lymphoma**  
Irene Scarfo, Massachusetts General Hospital Cancer Center, Charlestown, MA

11:45 a.m.-1:45 p.m.  **Poster Session B / Lunch**  
Salon F

Therapeutics and Clinical Trials in Lymphoma 2

Lymphoid Cancers 2

Pathology and Classification of Lymphomas

2:00 p.m.-4:00 p.m.  **Plenary Session 5: The Significance of Targeting the Microenvironment in Lymphoma**  
Salon E

**Session Chair:** Karin Tarte, University of Rennes, Rennes, France

2:00 p.m.-2:30 p.m.  **Ex vivo lymphoid tissue microenvironments to model epigenetics and signaling in healthy and malignant B cells**  
Ankur Singh, Cornell University, Ithaca, NY
2:30 p.m.-3:00 p.m.  Dissecting microenvironmental cues that promote B-cell lymphoma growth in secondary lymphoid organs  
Uta E. Höpken, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

3:00 p.m.-3:30 p.m.  Targeting cancer-associated fibroblasts to promote antitumor immunity  
Hélène Salmon, Icahn School of Medicine at Mount Sinai, New York, NY

3:30 p.m.-4:00 p.m.  Panel discussion  
Uta E. Höpken  
Hélène Salmon  
Ankur Singh  
Karin Tarte

4:00 p.m.-4:30 p.m.  Break  
Salons A-E Foyer

4:30 p.m.-6:30 p.m.  Plenary Session 6: Follicular Lymphoma: When to Treat and How to Define Early Disease  
Salon E  
Session Chair: Bertrand Nadel, Centre d’Immunologie de Marseille-Luminy, Marseille, France

4:30 p.m.-4:55 p.m.  Committed precursor cells (CPC) and follicular lymphoma genesis  
Bertrand Nadel

4:55 p.m.-5:20 p.m.  Insights into early and late steps of follicular lymphoma pathogenesis from genomic studies  
Robert Kridel, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
5:20 p.m.-5:45 p.m.  Clinical and biologic criteria for treatment decision in follicular lymphoma
Gilles Salles, Lyon-Sud Charles Mérieux Medical School, Pierre Bénite, France

5:45 p.m.-6:10 p.m.  Front-line chemotherapy-free treatments for follicular lymphoma?
Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

6:10 p.m.-6:30 p.m.  Panel discussion
Robert Kridel
Bertrand Nadel
Gilles Salles
Emanuele Zucca

6:30 p.m.  Dinner on own

MONDAY, JUNE 25

7:00 a.m.-8:00 a.m.  Breakfast
Salon F

7:15 a.m.-8:00 a.m.  Concurrent Sessions 5-6

Concurrent Session 5: What Is the Molecular Basis and Most Promising Road towards Molecular Targeted Therapies for Double-Hit Lymphoma?
Salons B-D

Session Chair: David M. Weinstock, Dana-Farber Cancer Institute, Boston, MA
The laboratory challenge of double-hit lymphoma
David M. Weinstock

The clinical challenge of double-hit lymphoma
Philippe Armand, Dana-Farber Cancer Institute, Boston, MA

Panel discussion
Philippe Armand
David M. Weinstock

Concurrent Session 6: What Do Mutation Profiles Teach Us about Rare versus Common Forms of Lymphoma?
Salon E

Session Chair: Sandeep S. Dave, Duke University, Durham, NC

Rare vs. common: Using genomic discoveries for a unified view of lymphoma
Sandeep S. Dave

Pathways to clinical translation of genetic discoveries
Eric D. Hsi, The Cleveland Clinic, Cleveland, OH

Panel discussion
Sandeep S. Dave
Eric D. Hsi
8:00 a.m.-10:30 a.m. **Plenary Session 7: How Do Clonal Dynamics and Tumor Heterogeneity Factor into Clinical Outcome and Therapy?**

**Salon E**

**Session Chair:** Dan A. Landau, Weill Cornell Medical College, New York, NY

8:00 a.m.-8:30 a.m. 3'-UTR disruption of PD-L1 in malignant lymphomas

Seishi Ogawa, Kyoto University Graduate School of Medicine, Kyoto, Japan

8:30 a.m.-9:00 a.m. Actionable molecular heterogeneity in DLBCL

Bjoern Chapuy, Dana-Farber Cancer Institute, Boston, MA

9:00 a.m.-9:30 a.m. Epigenetic determinants of normal and malignant somatic evolution

Dan A. Landau

9:30 a.m.-9:45 a.m. Ibrutinib does not suppress clonal evolution in high-risk chronic lymphocytic leukemia

Davide Rossi, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland

9:45 a.m.-10:00 a.m. Genetic landscape of extranodal marginal zone (MALT) lymphomas

Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland

10:00 a.m.-10:30 a.m. **Panel discussion**

Francesco Bertoni
Bjoern Chapuy
Dan A. Landau
Seishi Ogawa
Davide Rossi
10:30 a.m.-11:00 a.m. **Break**
Salons A-E Foyer

11:00 a.m.-11:30 a.m. **Spotlight on Proferred Papers Session 3**
(from posters in Session C)
Salon E

11:00 a.m.-11:15 a.m. **HSF1 orchestrates a prolymphomagenic microenvironment through matrix remodeling and deficient lymphoma immunity**
Jude M. Phillip, Weill Cornell Medicine, New York, NY

11:15 a.m.-11:30 a.m. **The ETS inhibitors YK-4-279 and TK-216 synergize with lenalidomide via SPIB downregulation in diffuse large B-cell lymphoma of the activated B cell-like type (ABC DLBCL)**
Filippo Spriano, Institute of Oncology Research, Bellinzona, Switzerland

11:45 a.m.-1:45 p.m. **Poster Session C / Lunch**
Salon F

Basic and Translational Science 2

Diagnostic and Prognostic Biomarkers

Ethnicity as a Risk Factor in Cancer Disparities

Therapeutics and Clinical Trials in Lymphoma 3
CONFERENCE SCHEDULE

2:00 p.m.-4:00 p.m.  Plenary Session 8: What Is the Role for Checkpoint Protein Functionality and Therapeutic Blockade in Lymphoma?  
Salon E  
Session Chair: Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, MA  
2:00 p.m.-2:30 p.m.  Exploiting epigenetic and immune vulnerabilities in lymphoma  
Ricky W. Johnstone, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia  
2:30 p.m.-3:00 p.m.  Targetable genetic bases of immune evasion in lymphoma  
Margaret A. Shipp  
3:00 p.m.-3:30 p.m.  In situ vaccination for lymphoma  
Ronald Levy, Stanford University, Stanford, CA  
3:30 p.m.-4:00 p.m.  Panel discussion  
Ronald Levy  
Margaret A. Shipp  
4:00 p.m.-4:30 p.m.  Break  
Salons A-E Foyer  

4:30 p.m.-6:30 p.m.  Plenary Session 9: How Can We Improve the Outcome of Patients with PTCL?  
Salon E  
Session Chair: Kerry Savage, University of British Columbia, Vancouver, BC, Canada  
4:30 p.m.-4:55 p.m.  How do we raise the therapeutic bar in PTCLs?  
Kerry Savage  
4:55 p.m.-5:20 p.m.  Genomics and pathobiology of PTCL  
Wing C. Chan, City of Hope, Duarte, CA
5:20 p.m.-5:45 p.m.  **PDX models in T-cell lymphoma**  
David M. Weinstock, Dana-Farber Cancer Institute, Boston, MA

5:45 p.m.-6:00 p.m.  **Novel drug combinations**  
Neha Mehta-Shah, Washington University Medical School, St. Louis, MO

6:00 p.m.-6:30 p.m.  **Panel discussion**  
Wing C. Chan  
Neha Mehta-Shah  
Kerry Savage  
David M. Weinstock

6:30 p.m.  **Dinner on own**

**TUESDAY, JUNE 26**

7:00 a.m.-8:00 a.m.  **Breakfast**  
Salons B-D

8:00 a.m.-10:00 a.m.  **Keynote Lectures**  
Salon E

8:00 a.m.-8:45 a.m.  **Immune checkpoint blockade in cancer therapy: New insights, opportunities, and prospects for cures**  
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, TX

8:45 a.m.-9:30 a.m.  **Targeting Achilles heels in multiple myeloma**  
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA
CONFERENCE SCHEDULE

Keynote Lectures (cont’d)

9:30 a.m.-10:00 a.m.  Panel discussion
James P. Allison
Kenneth C. Anderson
Ari M. Melnick

10:00 a.m.-10:15 a.m.  Break
Salons A-E Foyer

10:15 a.m.-12:15 p.m.  Plenary Session 10:
Transforming First-Line Therapy for Hodgkin and Non-Hodgkin Lymphoma
Salon E

Session Chair: Thomas E. Witzig, Mayo Clinic College of Medicine, Rochester, MN

10:15 a.m.-10:45 a.m.  Standard of care in 2018 for DLBCL: Setting the stage for the next NCTN trials
Thomas E. Witzig

10:45 a.m.-11:15 a.m.  Transforming the front-line care of PTCL
Owen A. O’Connor, Columbia University Medical Center, New York, NY

11:15 a.m.-11:45 a.m.  Title to be announced
Kerry Savage, University of British Columbia, Vancouver, BC, Canada

11:45 a.m.-12:15 p.m.  Panel discussion
Owen A. O’Connor
Kerry Savage
Thomas E. Witzig

12:15 p.m.-12:30 p.m.  Meeting Highlights: Promise for the Future
Salon E

Ari M. Melnick, Weill Cornell Medical College, New York, NY